Cargando…
Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model
Squamous cell carcinoma of oral cavity (OCSCC) accounts for approximately 25% of cases of head and neck squamous cell carcinoma (HNSCC). Tobacco and alcohol consumption are the main risk factors for both cancers. Surgical resection, combined with adjuvant radiotherapy or radiochemotherapy in patient...
Autores principales: | Gutiérrez Calderón, Vanesa, Cantero González, Alexandra, Gálvez Carvajal, Laura, Aguilar Lizarralde, Yolanda, Rueda Domínguez, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905482/ https://www.ncbi.nlm.nih.gov/pubmed/33747147 http://dx.doi.org/10.1177/1758835920984061 |
Ejemplares similares
-
Liquid Biopsy as a Tool for the Characterisation and Early Detection of the Field Cancerization Effect in Patients with Oral Cavity Carcinoma
por: Pérez-Ruiz, Elisabeth, et al.
Publicado: (2021) -
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
por: Shibata, Hirofumi, et al.
Publicado: (2021) -
Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer
por: Bell, R. Bryan, et al.
Publicado: (2022) -
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022) -
A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma
por: Nindra, Udit, et al.
Publicado: (2023)